<?xml version="1.0" encoding="UTF-8"?>
<p id="Par39">World Health Organization (WHO) describes diabetes as a disturbance in the metabolism of carbohydrates, fats protein; generated by the deficit of insulin deliverance, or decreased susceptibility of the tissue to insulin (Kavitha and Dattatri 
 <xref ref-type="bibr" rid="CR170">2013</xref>). Allopathic medications are not enough, therefore naturally occurring medicinally active plants impart a crucial role in the cure of diabetes mellitus (Dabe and Kefala 
 <xref ref-type="bibr" rid="CR82">2017</xref>). The aerial root extracts of 
 <italic>A. dracunculus</italic> were evaluated for antidiabetic effect in streptozotocin (STZ) promoted diabetic rats. It showed a promising and remarkable antihyperglycemic effect when compared with standard drug glibenclamide at a dose of 0.25Â mg/kg. The plant was capable of enacting antidiabetic, along with antihyperlipidemic properties (Samyal et al. 
 <xref ref-type="bibr" rid="CR295">2011</xref>). The antidiabetic efficacy of 
 <italic>A. amygdalina</italic> being effective in hyperglycemia may successfully control metabolic disorder and endorse its medicinal therapeutics and conventional uses (Sidhu and Sharma 
 <xref ref-type="bibr" rid="CR311">2013</xref>; Ghazanfar et al. 
 <xref ref-type="bibr" rid="CR110">2014</xref>). 
 <italic>A. dracunculus</italic> L. was found to contain a hypoglycaemic effect by numerous investigators (Ribnicky et al. 
 <xref ref-type="bibr" rid="CR289">2009</xref>; Wang et al. 
 <xref ref-type="bibr" rid="CR355">2011</xref>). Wang et al. (
 <xref ref-type="bibr" rid="CR355">2011</xref>) ascertained a particular 
 <italic>A. dracunculus</italic> L. plant for its prominent insulin susceptibility as well as insulin resistant (IR) signaling in insulin-resistant KK-Ay mice but are unable to describe the appropriate cellular mechanism (Coman et al. 
 <xref ref-type="bibr" rid="CR79">2012</xref>).
</p>
